Who are Oral intake of medication's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trintellix, Lexapro, Zoloft, Prozac, High severity group: Escitalopram, Low severity group: Escitalopram.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-intake-of-medication.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Oral intake of medication — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral intake of medication (Oral intake of medication) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SSRI. Area: Psychiatry.

marketed SSRI Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Oral intake of medication (Oral intake of medication) — Beni-Suef University. This drug works by inhibiting the reuptake of serotonin and norepinephrine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral intake of medication TARGET	Oral intake of medication	Beni-Suef University	marketed	SSRI
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Lexapro	escitalopram	Generic (originally Lundbeck/Forest)	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin (5-HT) reuptake transporter	2002-08-14
Zoloft	sertraline	Pfizer Inc.	marketed	SSRI (Selective serotonin reuptake inhibitor)	Cytochrome P450 2C19, Melanocortin receptor 5, 5-hydroxytryptamine receptor 2A	1991-12-30
Prozac	fluoxetine	Eli Lilly and Company	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter	1987-12-29
High severity group: Escitalopram	High severity group: Escitalopram	University of Texas Southwestern Medical Center	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Low severity group: Escitalopram	Low severity group: Escitalopram	University of Texas Southwestern Medical Center	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SSRI class)

Washington University School of Medicine · 2 drugs in this class
Astellas Pharma Inc · 1 drug in this class
Beni-Suef University · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Centre of Clinical Pharmacology, Hanoi Medical University · 1 drug in this class
Chonbuk National University Hospital · 1 drug in this class
EMS · 1 drug in this class
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 1 drug in this class
PMG Pharm Co., Ltd · 1 drug in this class
PT Bio Farma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral intake of medication — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-intake-of-medication. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab